Management ChangeAug 5, 2026, 04:32 PM
PacBio Appoints Mark Van Oene CEO; Announces Restructuring & Q2 Results
AI Summary
Pacific Biosciences of California, Inc. announced the appointment of Mark Van Oene as its new President and CEO, effective August 5, 2026, succeeding Christian Henry, who will remain on the Board. The company also approved a restructuring plan, including a workforce reduction of approximately 40 employees (8%), aiming to reduce annualized operating expenses by $30M-$40M by the end of 2027. For Q2 2026, PacBio reported total revenue of $39.0 million and a GAAP net loss of $44.7 million, and provided full-year 2026 revenue guidance of $155 million to $165 million.
Key Highlights
- Mark Van Oene appointed President and CEO, effective August 5, 2026.
- Christian Henry stepped down as CEO, remains on Board and as advisor.
- Restructuring plan to reduce workforce by approximately 40 employees (8%).
- Expected $30M-$40M annualized operating expense reduction by end 2027.
- Estimated $2.0M pre-tax charges for restructuring in Q3 2026.
- Q2 2026 total revenue $39.0M, down from $39.8M in Q2 2025.
- Q2 2026 GAAP net loss $44.7M, compared to $41.9M in Q2 2025.
- Full-year 2026 revenue guidance set at $155M to $165M.
Price Impact
More from PACB